Arcadia Biosciences
RKDA
28 hedge funds and large institutions have $640K invested in Arcadia Biosciences in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
17% more funds holding
Funds holding: 24 → 28 (+4)
0.09% less ownership
Funds ownership: 0.33% → 0.24% (-0.09%)
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
63% less capital invested
Capital invested by funds: $1.73M → $640K (-$1.09M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$64.6K |
| 2 |
Millennium Management
New York
|
+$53.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$46.2K |
| 4 |
HF
HRT Financial
New York
|
+$29.6K |
| 5 |
E
Ergoteles
New York
|
+$16.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$382K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$158K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$10.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$8K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$6.75K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HI
26
Harbour Investments
Madison,
Wisconsin
| $6 | – | – | – |
|
|
27
UBS Group
Zurich,
Switzerland
| – | -$8K | -392 | Closed |
|
28
Fidelity Investments
Boston,
Massachusetts
| – | -$5K | -250 | Closed |
|
|
AIM
29
Axiom Investment Management
New York
| – | -$1K | -38 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$171 | -12 | -92% |
|
31
Simplex Trading
Chicago,
Illinois
| – | +$85 | +6 | New |
|
RKDA Hedge Fund Activity: Q4 2022 in Review
28 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q4 2022, worth a combined $640K — down 63% from $1.73M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RKDA positions and 3 closed out — a net gain of 4 holders — while 5 added to existing stakes and 12 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $64.6K. The largest seller was Armistice Capital, cutting an estimated $382K.
- 28 institutional investors held Arcadia Biosciences (RKDA) as of Q4 2022, up from 24 in Q3 2022.
- Funds reported $640K of Arcadia Biosciences stock for Q4 2022, down 63% quarter-over-quarter.
- 7 funds opened new Arcadia Biosciences positions in Q4 2022 and 3 closed out, a net change of +4 holders.
- The largest Arcadia Biosciences buyer in Q4 2022 was Citadel Advisors, an estimated $64.6K added.
- The largest Arcadia Biosciences seller in Q4 2022 was Armistice Capital, an estimated $382K sold.
Based on aggregated 13F filings for Q4 2022.